Workflow
Nectin Therapeutics Licenses Novel Antibodies to Immunome
ImmunomeImmunome(US:IMNM) Prnewswireยท2024-07-25 11:30

Core Insights - Nectin Therapeutics has entered into an exclusive worldwide license agreement with Immunome for a panel of antibodies targeting an undisclosed target, allowing Immunome to develop and commercialize these antibodies [2][4] - The agreement enables Nectin to focus on its first-in-class anti-PVR program (NTX1088) and advance its novel antibody drug conjugates (ADCs) into clinical development [4] Company Overview - Nectin Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies and ADCs to combat tumor resistance, with a diverse pipeline aimed at addressing major escape mechanisms of current immuno-oncology therapies [3] - The company is backed by several venture funds, including aMoon Fund, Peregrine Ventures, and the Cancer Focus Fund, and has a strong management team with extensive experience in oncology drug development [3] Strategic Implications - The partnership with Immunome is seen as a strategic move for Nectin to realize value from its assets while continuing to advance its clinical studies in high unmet need tumor types [4] - Immunome's expertise in developing and commercializing ADC therapies positions it as an ideal partner for Nectin to enhance the development of its promising assets [4]